Clinical and laboratory observations of tuberculosis at a Mumbai (India) clinic

Postgraduate Medical Journal

Volumn 80, Issue 940, 2004, Pages 97-100

  Gothi, D ^a   Joshi, J M ^a  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; ARTICLE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INFORMED CONSENT; LABORATORY TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PATIENT COUNSELING; SCHOOL CHILD; SERODIAGNOSIS; SPUTUM ANALYSIS; SPUTUM SMEAR; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPECIMEN HANDLING; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 1542299173     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.2003.008185     Document Type: Article

References (30)

1. Directorate General of Health Services and Family Welfare. Tuberculosis control - India. 12 October 2002 (www.tbcindia.org).
2. Grzybowski S. Drugs are not enough. Failure of short-course chemotherapy in a district in India. Tuberc Lung Dis 1993;74:145-6.
3. World Health Organisation. Report on the TB epidemic. WHO/TB/97.224. Geneva: WHO, 1997.
4. World Health Organisation. A clinical manual for South East Asia. Treatment of tuberculosis - guidelines for national programme. WHO/TB/96.200. Geneva: WHO, 1997.
5. Khatri GR. The Revised National Tuberculosis Control Programme: a status report on first 1,00,000 patients. Indian J Tuberc 1999;46:157-66.
6. Metchock BG, Nolte FS, Wallace RJ. Mycobacterium. In: Murray PR, Baron EJ, Pfallerm MA, Tenover FC, Yokken RH, eds. Manual of clinical microbiology. 7th Ed. Washington, DC: ASM Press, 1999:399-437.
7. Warren JR, Bhattacharya M, De Almeida KN, et al. A minimum 5.0 ml of sputum improves the sensitivity of acid-fast smear for Mycobacterium tuberculosis. Am J Respir Crit Care Med 2000;161:1559-62.
8. Della-Latta P, Whittier S. Comprehensive evaluation of performance, laboratory application, and clinical usefulness of two direct amplification techniques for detection of Mycobacterium tuberculosis complex. Am J Clin Pathol 1998;110:301-10.
9. Kim TC, Blackman RS, Heatwole KM, et al. Acid-fast-bacilli in sputum smears of patients with pulmonary tuberculosis. Am Rev Respir Dis 1984;129:264-8.
10. Dutt AK, Stead WW. Short course chemotherapy. The Arkansas experience. Chest 1981;80:724-7.
11. Gunnels JJ, Bates JH, Swindoll H. Infectivity of sputum positive tuberculosis patients on chemotherapy. Am Rev Respir Dis 1974;109:323-30.
12. Narain R, Subba Rao MS, Chandrashekhar P, et al. Microscopy positive and microscopy negative cases. Am Rev Respir Dis 1971;103:761-3.
13. Ormerod LP. Respiratory tuberculosis. In: Davies PDO, ed. Clinical tuberculosis. 2nd Ed. London: Chapman & Hall, 1998:155-74.
14. Anglaret X, Saba J, Perronne C, et al. Empiric antituberculosis treatment benefits for earlier diagnosis and treatment of tuberculosis. Tuberc Lung Dis 1994;75:334-50.
15. Mohanty KC, Pasi RB. Incidence of HIV infection in TB. Proceedings of the National Conference on TB and Chest Disease. Mumbai, 1992.
16. Benvelikar JN. HIV seropositivity in hospitalized patients in Delhi. Indian J Tuberc 1997;44:17-20.
17. Vasade W. HIV infection among tuberculosis patients. Indian J Tuberc 1997;44:97-8.
18. Gupta PR. TB in HIV seropositive patients in Rajasthan. Lung India 1998;16:147-9.
19. Rathi PM, Amarapurkar DN, Parikh SS, et al. Impact of human immunodeficiency virus infection on abdominal TB in Western India. J Clin Gastroenterol 1997;24:43-8.
20. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21.
21. Perlman DC, el-Sard MW, Nelson ET, et al. Chest radiographic pattern in pulmonary tuberculosis by degree of human immunodeficiency virus related immunosuppression: the Terry Beim progress for clinical research in AIDS (CPCRA). Clin Infect Dis 1997;25:242-6.
22. Halvir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999;340:367-73.
23. Advisory Committee for the Elimination of Tuberculosis. Tuberculosis and human immunodeficiency virus infection: recommendation of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR Morb Mortal Wkly Rep 1989;38:236-8, 243-50.
24. Godfrey-Faussett P, Maher D, Mukadi YD, et al. How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ 2002;80:939-45.
25. Kaul S. The Revised National TB Control Programme and the DOTS strategy. Excerpts from an observational study in three districts. 1998 (www.ctrlaltesc.org/fighttb/02/02/11/102207.shtml).
26. Balasubramonium VN, Dommen K, Samuel R. DOT or not? Direct observation of anti tuberculosis treatment and patient outcomes, Kerala State, India. Int J Tuberc Lung Dis 2000;4:409-13.
27. Santha T, Garg R, Frieden TR, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 2002;6:780-8.
28. Walley JD, Khan MA, Newell JN, et al. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomized controlled trial in Pakistan. Lancet 2001;357:664-9.
29. Tandon M, Gupta M, Tandon S, et al. DOTS versus self-administered therapy (SAT) for patients of pulmonary tuberculosis: a randomized trial at a tertiary care hospital. Indian J Med Sci 2002;56:19-21.
30. Zwarenstein M, Schoeman JH, Vundule C, et al. Randomized controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998;352:1340-3.